266 related articles for article (PubMed ID: 38244292)
1. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic.
Guo Y; Cheng R; Wang Y; Gonzalez ME; Zhang H; Liu Y; Kleer CG; Xue L
EBioMedicine; 2024 Feb; 100():104972. PubMed ID: 38244292
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
[TBL] [Abstract][Full Text] [Related]
3. Post-translational modifications of EZH2 in cancer.
Li Z; Li M; Wang D; Hou P; Chen X; Chu S; Chai D; Zheng J; Bai J
Cell Biosci; 2020 Dec; 10(1):143. PubMed ID: 33308321
[TBL] [Abstract][Full Text] [Related]
4. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Zhang T; Gong Y; Meng H; Li C; Xue L
Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
[TBL] [Abstract][Full Text] [Related]
5. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Xia J; Li J; Tian L; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
[TBL] [Abstract][Full Text] [Related]
6. Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
Wang C; Chen X; Liu X; Lu D; Li S; Qu L; Yin F; Luo H; Zhang Y; Luo Z; Cui N; Kong L; Wang X
Eur J Med Chem; 2022 Aug; 238():114462. PubMed ID: 35623249
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer.
Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
[TBL] [Abstract][Full Text] [Related]
8. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
Lu H; Li G; Zhou C; Jin W; Qian X; Wang Z; Pan H; Jin H; Wang X
Am J Cancer Res; 2016; 6(12):2737-2754. PubMed ID: 28042497
[TBL] [Abstract][Full Text] [Related]
9. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
[TBL] [Abstract][Full Text] [Related]
10. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
11. Targeting EZH2 for cancer therapy: progress and perspective.
Han Li C; Chen Y
Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
Liu Z; Hu X; Wang Q; Wu X; Zhang Q; Wei W; Su X; He H; Zhou S; Hu R; Ye T; Zhu Y; Wang N; Yu L
J Med Chem; 2021 Mar; 64(5):2829-2848. PubMed ID: 33606537
[TBL] [Abstract][Full Text] [Related]
13. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.
Wang X; Cao W; Zhang J; Yan M; Xu Q; Wu X; Wan L; Zhang Z; Zhang C; Qin X; Xiao M; Ye D; Liu Y; Han Z; Wang S; Mao L; Wei W; Chen W
EMBO J; 2017 May; 36(9):1243-1260. PubMed ID: 28320739
[TBL] [Abstract][Full Text] [Related]
14. USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization.
Park JM; Lee JE; Park CM; Kim JH
Mol Cells; 2019 Jan; 42(1):17-27. PubMed ID: 30622230
[TBL] [Abstract][Full Text] [Related]
15. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma.
Tu Y; Sun Y; Qiao S; Luo Y; Liu P; Jiang ZX; Hu Y; Wang Z; Huang P; Wen S
J Med Chem; 2021 Jul; 64(14):10167-10184. PubMed ID: 34196564
[TBL] [Abstract][Full Text] [Related]
17. Targeting EZH2 for cancer therapy: From current progress to novel strategies.
Zeng J; Zhang J; Sun Y; Wang J; Ren C; Banerjee S; Ouyang L; Wang Y
Eur J Med Chem; 2022 Aug; 238():114419. PubMed ID: 35569264
[TBL] [Abstract][Full Text] [Related]
18. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
19. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
20. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]